Corcept Therapeutics Incorporated (CORT)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.24 | 1.23 | 1.16 | 1.13 | 1.09 |
Corcept Therapeutics Incorporated demonstrates exceptional solvency as evidenced by its solvency ratios. The Debt-to-assets ratio, Debt-to-capital ratio, and Debt-to-equity ratio have consistently been 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has no debt relative to its assets, capital, or equity, implying low financial risk associated with debt obligations.
Furthermore, the Financial leverage ratio has shown a slight increasing trend, rising from 1.09 on December 31, 2020, to 1.24 by December 31, 2024. This ratio measures the proportion of a company's assets that are financed with debt compared to equity. Despite the increase, the ratios are relatively low, indicating a conservative capital structure and financial stability.
Overall, based on these solvency ratios, Corcept Therapeutics Incorporated appears to be in a strong financial position with minimal debt levels and a conservative approach to financing its operations, thereby enhancing its ability to meet financial obligations and weather economic uncertainties.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | — | — | 31.67 | 34.62 | 22.74 |
Interest coverage ratio is a financial metric used to evaluate a company's ability to cover its interest expenses with its operating income. It indicates the firm's capacity to meet interest obligations on its outstanding debt. In the case of Corcept Therapeutics Incorporated, the interest coverage ratio has shown a positive trend over the years.
As of December 31, 2020, the interest coverage ratio stood at 22.74, indicating that the company earned 22.74 times the amount needed to cover its interest expenses. This shows a strong ability to meet interest obligations.
By December 31, 2021, the interest coverage ratio improved further to 34.62, reflecting the company's enhanced ability to service its debt obligations with its operating income.
In the following years, the interest coverage remained healthy, with ratios of 31.67 by December 31, 2022. However, the data is not available for the subsequent years, 2023 and 2024.
Overall, the consistently high interest coverage ratios indicate that Corcept Therapeutics Incorporated has a strong financial position and is capable of comfortably meeting its interest payments with its operating income.